Compare Twilio Inc (TWLO) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Twilio Inc vs GeneDx Holdings Corp — how do they compare? Twilio Inc trades at $289.47 (market cap $42.35B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Twilio Inc is far larger — about 21× GeneDx Holdings Corp's market cap, and Twilio Inc is trading nearer its 52-week high, GeneDx Holdings Corp nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twilio Inc for 56 Days and GeneDx Holdings Corp for 19 Days on average.
| TWLO | WGS | |
|---|---|---|
Market Cap | $42.35B | $2.02B |
Volume | 1,862,642 | 734,640 |
Sector | Technology | Health |
52-Week High | $301.27 | $167.51 |
52-Week Low | $106.23 | $34.51 |
Typical Hold Time | 56 Days | 19 Days |
Enterprise Value | $40.76B | $2.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Twilio (TWLO) trades at $275.77, up 1.01% with a bullish technical signal. The company shows strong fundamental improvement with revenue growing from $3.8B in 2022 to $5.1B in 2025, achieving positive net income of $34M after years of losses. Recent Q2 2026 earnings beat expectations with EPS of $1.47 versus $1.32 expected. The stock's inclusion in the S&P 500 index effective October 6, 2026, provides institutional validation and potential index fund inflows.
Twilio presents a compelling growth story with accelerating revenue and profitability, though valuation remains elevated at P/E 38.09. Key risks include competitive pressures in customer engagement software and execution challenges in maintaining growth momentum. Analyst consensus remains strongly bullish with 77% buy ratings, though the current price exceeds the $254.65 consensus target, suggesting near-term caution may be warranted despite positive long-term prospects.
GeneDx (WGS) trades at $67.33, down 1.75% today, with a mixed technical picture showing bearish moving averages but oversold RSI readings. The company reported Q2 2026 revenue of $114.4M, beating expectations with a return to adjusted profitability, though full-year 2026 shows negative net margins. Recent news highlights product launches and positive analyst coverage with 91% buy ratings.
While analyst consensus is strongly bullish with an $81 price target, fundamental risks remain due to negative profitability and high valuation multiples. The stock offers potential upside if operational improvements continue, but investors face execution risk amid ongoing losses and competitive pressures in the genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Twilio Inc
Twilio Inc. is a cloud-based communication platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces, or APIs, and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.
Read more on TWLO →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
